- Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway
Cai-Zhi Yang et al, 2023, Journal of Ethnopharmacology CrossRef - Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis
Xiao-Yan Liu et al, 2024, World Journal of Gastrointestinal Surgery CrossRef - Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
Wanhong Xu et al, 2019, Neoplasia CrossRef - Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications
Tiziana Tataranni et al, 2019, Oxidative Medicine and Cellular Longevity CrossRef - Genes associated with diagnosis and prognosis of Burkitt lymphoma
Albert Doughan et al, 2022, IET Systems Biology CrossRef - EGFR‐rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathway‐suppressed ROS
Fei Li et al, 2020, Journal of Extracellular Vesicles CrossRef - Oestrogen receptor β5 and epidermal growth factor receptor synergistically promote lung cancer progression
Yuquan Bai et al, 2018, Autoimmunity CrossRef - CT2-3, a novel magnolol analogue suppresses NSCLC cells through triggering cell cycle arrest and apoptosis
Jian Chen et al, 2020, Bioorganic & Medicinal Chemistry CrossRef - Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor
Yaoshuai Zhang et al, 2023, European Journal of Pharmacology CrossRef - Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
Alexandre F. Aissa et al, 2021, Nature Communications CrossRef - Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
Nan Wei et al, 2020, Frontiers in Oncology CrossRef - Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
Piyada Sitthideatphaiboon et al, 2022, Scientific Reports CrossRef